The Effectiveness of ACB-IP 1.0 Convalescent Plasma in COVID-19 Infection
1 other identifier
observational
40
1 country
2
Brief Summary
Pathogen-free, concentrated, pooled convalescent plasma has higher SARS-CoV2 antibody titers and neutralizing antibody activities, without requiring blood group compatibility that allows patient accessibility in a shorter time and has safe plasma characteristic.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Feb 2021
Shorter than P25 for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 15, 2021
CompletedStudy Start
First participant enrolled
February 18, 2021
CompletedFirst Posted
Study publicly available on registry
February 24, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2021
CompletedFebruary 24, 2021
February 1, 2021
1 month
February 15, 2021
February 23, 2021
Conditions
Outcome Measures
Primary Outcomes (2)
Mortality Rate
A mortality rate is a measure of the frequency of occurrence of death in a defined population during a specified interval.
6 Months
Length of Hospitalization
The average length of stay in hospitals (ALOS) is often used as an indicator of efficiency
6 Months
Secondary Outcomes (1)
Side Effects
6 Months
Study Arms (2)
Single donor convalescent plasma
Patients who had positive reverse-transcriptase-polymerase-chain-reaction (RT-PCR) for SARS-CoV2 and radiologically confirmed pneumonia treated with single donor plasma
ACB- IP 1.0
Patients who had positive reverse-transcriptase-polymerase-chain-reaction (RT-PCR) for SARS-CoV2 and radiologically confirmed pneumonia treated with ACB- IP 1.0 pathogen-free concentrated cocktail convalescent plasma
Eligibility Criteria
Adults with positive reverse-transcriptase-polymerase-chain-reaction (RT-PCR) for SARS-CoV2 and/or radiologically confirmed pneumonia, were included in the study.
You may qualify if:
- Are over the age of 60 or-
- Between the ages of 18-60, serious comorbidities (cancer, COPD, cardiovascular illness, hypertension, DM)
- Clinically diagnose COVID-19 or radiological diagnosed COVID-19 pnemonia
You may not qualify if:
- Multiple Organ Failure
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Acibadem Universitylead
- Acıbadem Labcellcollaborator
Study Sites (2)
Acıbadem Labcell Cellular Therapy Laboratories
Istanbul, 34758, Turkey (Türkiye)
Acibadem Altunizade Hospital
Istanbul, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 15, 2021
First Posted
February 24, 2021
Study Start
February 18, 2021
Primary Completion
April 1, 2021
Study Completion
June 1, 2021
Last Updated
February 24, 2021
Record last verified: 2021-02